Tag: HD-MAP
Vaxxas hits enrollment target in trial of HD-MAP technology for pandemic response
Australian biotechnology company Vaxxas has completed enrollment for its largest clinical trial to date, testing the safety and immune response of its high-density microarray patch (HD-MAP) for vaccine delivery.Â
Vaxxas unveils positive clinical trial results for needle-free COVID-19 vaccine
Australia biotechnology company Vaxxas said it achieved positive interim results from a Phase I human clinical trial with the first needle-free COVID-19 vaccine candidate.Â
Vaxxas kickstarts needle-free COVID-19 vaccine clinical trial
Australian biotechnology company Vaxxas has begun the Phase I clinical trial of the first needle-free COVID-19 vaccine candidate.Â
Vaxxas receives $8.2 million Commonwealth Government grant to support manufacturing scale-up in its Australian...
Media Release by Vaxxas
Vaxxas will receive an AU$8.2 million second-round grant as part of the Commonwealth Government’s Modern Manufacturing Initiative (MMI) to support the...
Construction commences of Australia’s first needle-free vaccine manufacturing facility
Vaxxas, a Queensland biotechnology business, has begun construction on a new facility in Northshore Hamilton, Brisbane to develop and manufacture its needle-free vaccination technology.
The...
Featured Article
APS Industrial expands regional footprint with Control Technologies acquisition
APS Industrial (APS) is expanding its regional presence through the acquisition of Albury-based Control Technologies, a move the industrial products supplier said will strengthen its local service capability and support further investment in warehousing, stockholding and technical support.
